PDCD1 and non-small cell lung carcinoma: In this project, we have critically reviewed and analyzed the best evidence available regarding the efficacy and safety of PD-1/PD-L1 inhibitors as monotherapy in the first-line treatment of advanced NSCLC and in several patient subgroups of clinical interest.